Corxel Pharmaceuticals raises $287M in a Series D1 funding round to advance its obesity drug CX11 into further testing.
Amount Raised
$287 Million
Round Type
Series D
Berkeley HeightsBiotechnologyHealth CareTherapeuticsInvestors
Description
Corxel Pharmaceuticals has successfully raised $287 million in a Series D1 funding round to advance the development of its obesity medication, CX11. The funding will support a global Phase 2 study in type 2 diabetes and additional late-stage trials. The company, based in New Jersey, focuses on innovative treatments for obesity and related conditions. With this capital, Corxel aims to accelerate its drug development efforts.
Quick answer
Corxel Pharmaceuticals raised $287 Million in a Series D round, dated January 22, 2026. Investors: Symbiosis, HBM Healthcare Investments, RA Capital Management, Tcgx and SR One. Corxel Pharmaceuticals is based in Berkeley Heights, New Jersey, United States.
- How much did Corxel Pharmaceuticals raise?
- Corxel Pharmaceuticals raised $287 Million in a Series D round on January 22, 2026.
- Who invested in Corxel Pharmaceuticals?
- Symbiosis, HBM Healthcare Investments, RA Capital Management, Tcgx and SR One are named as investors in this round.
- What does Corxel Pharmaceuticals do?
- Corxel Pharmaceuticals is a biotechnology company focused on developing innovative therapies for obesity and cardiometabolic diseases.
- Where is Corxel Pharmaceuticals based and how big is it?
- Corxel Pharmaceuticals is based in Berkeley Heights, New Jersey, United States. Fundz records about 53 employees.
- Who are the decision-makers at Corxel Pharmaceuticals?
- Fundz holds 4 contacts at Corxel Pharmaceuticals, including the Head of Biometrics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Corxel Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.
- Prolium Bioscience raised $50M (Series A) on March 5, 2026.
- NexCure raised $19M (Series A) on March 5, 2026.
- Os Therapies raised $2M on March 4, 2026.
- Antiverse raised $9.3M (Series A) on March 3, 2026.
- Polares Medical SA raised $50M (Series C) on March 3, 2026.
- KALA BIO, Inc. raised $1.8M on March 3, 2026.
Who to call at Corxel Pharmaceuticals, and when
A new round usually means Corxel Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Corxel Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Corxel Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Corxel Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Corxel Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Corxel Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.